Int roduct ion: The diagnosis of Marfan syndrome (MFS) depends on a mult idisciplinary clinical evaluat ion. Molecular st udy t o ident ify mut at ions in t he FBN1 gene can est ablish a defi nit ive diagnosis even wit h at ypical or " incomplet e" phenot ypes and enable earlier diagnosis in asympt omat ic pat ient s. Obj ect ives: The aim of t he present work was t o evaluat e t he frequency and t ype of FBN1 gene mut at ions in a populat ion of Marfan syndrome pat ient s referred t o a t ert iary care cent er wit h cardiot horacic surgery. Met hods: Our sample included 30 individuals wit h MFS (from 14 families), evaluat ed in cardiology, rheumat ology and opht halmology consult at ions. In all pat ient s, DNA was ext ract ed from a peripheral blood sample and mut at ion screening of t he ent ire coding sequence of t he FBN1 gene was t hen performed, using t he polymerase chain react ion. Result s: We ident ifi ed 12 different mut at ions in t he 14 families st udied. Of t hese, only t wo had been previously described in t he lit erat ure, while t he ot her 10 were found t o be new mut at ions; 36 % of pat ient s carried a missense mut at ion and 50 % carried a mut at ion leading t o a premat ure t erminat ion codon. Conclusions: To t he best of our knowledge t his is t he fi rst genot ypic descript ion of Port uguese pat ient s wit h MFS. In t his st udy, we highlight t he need for comprehensive clinical evaluat ion of t hese pat ient s and t he value of FBN1 mut at ion analysis in select ed cases. By describing 10 new mut at ions, we have also helped broaden t he spect rum of known FBN1 mut at ions associat ed wit h MFS.
Introduction
The diagnosis of Marfan syndrome (MFS) depends on a mult idisciplinary clinical evaluat ion and ident ifi cat ion of a set of diagnost ic crit eria, recent ly revised, known as t he Ghent crit eria 1 . The spect rum of clinical manifest at ions is very wide, but t ypically t he cardiovascular, musculoskelet al, and ocular syst ems are involved.
Molecular st udy t o ident ify mut at ions in t he FBN1 gene can est ablish a definit ive diagnosis even wit h at ypical or " incomplet e" phenot ypes. This gene, locat ed on chromosome 15q21.1, codes for a glycoprot ein, profi brillin-1, which is t hen convert ed t o fi brillin-1, a maj or component of ext racellular microfi brils. Over 600 different mut at ions have been described 2 , almost all unique t o an affect ed individual or family 3 .
Mut at ions may be found anywhere on t he FBN1 gene, and may be missense or lead t o a premat ure t erminat ion codon (PTC) 3 .
Of t he few genot ype-phenot ype correlat ions t hat have been est ablished, t he most not able is t he associat ion of neonat al MFS, t he most severe form of t he syndrome, wit h mut at ions in exons 24-32.
Early ident ifi cat ion of asympt omat ic carriers is desirable given t he high penet rance of mut at ions and t he morbidit y and mort alit y associat ed wit h MFS, mainly relat ed t o t he risk of aneurysm rupt ure and dissect ion of t he ascending aort a 4 . There are t reat ment s t hat can improve t he prognosis of t hese pat ient s if applied in t ime.
There are few published dat a concerning t he molecular diagnosis of pat ient s wit h MFS in t he Port uguese populat ion.
Objectives
The aim of t he present work was t o evaluat e t he frequency and t ype of FBN1 gene mut at ions in a populat ion of Marfan syndrome pat ient s referred t o a t ert iary care cent er wit h cardiot horacic surgery.
Methods

Identifi cation of index cases
Pat ient s were ident ified from t he hospit al's dat abase, covering a period of 20 years, bet ween January 1989 and December 2008. This dat abase includes all pat ient s at t ending consult at ions and/ or hospit alized in our inst it ut ion.
The select ion crit eria were current age of 18 years or over and a diagnosis of " Marfan syndrome" .
The adult pat ient s ident ifi ed were cont act ed by mail or t elephone and t heir physicians were informed t hat t hey pat ient s were t o be included in t he research proj ect .
All fi rst -degree relat ives of t he index cases were invit ed t o part icipat e in t he st udy.
Caracterização genotípica de uma população de doentes portugueses com síndrome de Marfan
Resumo Int rodução: O diagnóst ico da Síndrome de Marfan (SM) depende fundament alment e de uma avaliação clínica mult idisciplinar. O seu diagnóst ico molecular, at ravés da ident ifi cação de mut ações no gene FBN1, pode permit ir est abelecer um diagnóst ico defi nit ivo mesmo perant e fenót ipos at ípicos ou «incomplet os» e reconhecer precocement e port adores assint omát icos. Obj ect ivos: O present e t rabalho t eve como obj ect ivo principal avaliar a frequência e o t ipo de mut ações no gene FBN1, numa população de doent es com SM, referenciados a um cent ro hospit alar de cuidados t erciários, com cirurgia t orácica. Mét odos: A nossa amost ra incluiu 30 indivíduos com SM (provenient es de 14 famílias), que foram avaliados em consult a de Cardiologia, Reumat ologia e Oft almologia. Em t odos os casos foi efect uada a pesquisa de mut ações no gene FBN1 a part ir de ADN obt ido de amost ras de sangue periférico, ut ilizando a t écnica de amplifi cação por Polymerase Chain React ion e post erior sequenciação génica. Result ados: Ident ifi cámos 12 mut ações dist int as nas 14 famílias est udadas. Dest as, apenas 2 est avam previament e descrit as na lit erat ura, sendo as rest ant es 10, novas mut ações. Encont rámos mut ações missense em 36 % dos casos e mut ações conduzindo à formação de codões de t erminação premat ura em 50 % dos casos. Conclusões: Est e t rabalho const it ui a primeira descrição de result ados de análise genot ípica em doent es port ugueses com SM, de que t emos conheciment o. Com est e t rabalho, realçamos a import ância de uma avaliação clínica mult idisciplinar e da ut ilidade da pesquisa de mut ações no gene FBN1 em casos seleccionados. Ao descrever 10 novas mut ações, cont ribuímos ainda para a ampliação do espect ro de variant es do gene da FBN1 associadas à SM.
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Clinical assessment
All part icipant s were evaluat ed or re-evaluat ed in cardiology, rheumat ology and opht halmology consult at ions bet ween Oct ober 2008 and May 2009. Echocardiographic exams were performed by t wo experienced operat ors, using Vivid 3 (GE Healt hcare) or iE33 (Philips) scanners, and measurement s were made in accordance wit h t he guidelines of t he American Societ y of Echocardiography and t he European Associat ion of Echocardiography 5 .
Images were acquired in left parast ernal, apical, suprast ernal and subcost al planes. Aort ic root diamet er was measured in parast ernal long-axis view at t he level of t he sinuses of Valsalva and t he sinot ubular j unct ion of t he ascending aort a, and t he diamet ers of t he aort ic arch and t he descending t horacic aort a were measured in suprast ernal view.
Aort ic root dilat at ion was considered t o be present when t he diamet er measured at t he sinuses of Valsalva exceeded t he upper normal limit adj ust ed for t he pat ient 's age and body surface area 6 .
The presence of scoliosis and prot rusio acet abuli was det ermined from X-rays of t he spinal column and hip, respect ively, in rheumat ology consult at ions. The cut aneous crit eria for MFS were assessed in dermat ology consult at ions.
Respirat ory syst em involvement was assessed t hrough t he clinical hist ory, pat ient s being asked about previous pneumot horax.
The presence of ect opia lent is was invest igat ed in all pat ient s in opht halmology consult at ions.
Molecular study
DNA was ext ract ed from a peripheral blood sample and mut at ion screening of t he ent ire coding sequence of t he FBN1 gene (65 exons) was t hen performed using t he polymerase chain react ion (PCR).
If no mut at ions were ident ified by t his t echnique, mult iplex ligat ion-dependent probe amplificat ion (MLPA) was used t o det ect gene rearrangement s. All posit ive result s were confirmed by repeat ing t he ent ire analysis.
In cases of mut at ions not previously described in t he lit erat ure (t he UMD dat abase) 2 , pat hogenicit y was invest igat ed by comparison wit h t he Ensembl nucleot ide polymorphism dat abase 7 and using t he PolyPhen algorit hm (PolyPhen dat abase) 8 .
Statistical analysis
The st at ist ical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Cont inuous variables are present ed as means ± st andard deviat ion, or as medians (int erquart ile range) in t he case of non-normal dist ribut ion. Cat egorical variables are present ed as frequency count s and percent ages. Differences bet ween means were assessed by t he St udent 's t t est for independent samples, except for non-normal dist ribut ions, for which t he Mann-Whit ney U t est was used. A value of p <0.05 was used t o rej ect t he null hypot hesis.
Results
The st udy populat ion included 30 individuals wit h MFS from 14 unrelat ed families (14 index cases and 16 relat ives), 57 % male, mean age 37±12 years.
Of t hese, 27 (90 %) present ed maj or cardiovascular crit eria; 13 (43 %) had undergone surgical aort ic root replacement , 43 % had mit ral valve prolapse, 23 % evidence of aort ic dissect ion and 23 % dilat at ion of t he descending aort a. Regarding medicat ion, 19 pat ient s (63 %) were t aking bet a-blockers, six (20 %) angiot ensin-convert ing enzyme inhibit ors, and seven (23 %) angiot ensin II recept or blockers.
The prevalences of t he Ghent crit eria are shown in Table 1 .
Genet ic st udy was performed in t he 14 index cases and in 22 relat ives (16 wit h posit ive genet ic t est and 8 wit h no FBN1 mut at ion ident ifi ed). The result s of molecular st udy and t heir correlat ion wit h t he presence of MFS crit eria are shown in Table 2 .
Twelve different mut at ions were ident ified in t he 14 families: t en new and t wo known (cases 8 and 13, mut at ions Cys2111Arg 2 and Arg861X 9 ). One pat ient had t wo different mut at ions. The mut at ions were ident ifi ed in funct ionally dist inct domains: t hree in TGF-␤-like domains, six in cbEGF-like domains, t wo in hybrid domains, and one in t he t erminal COOH region.
In t hree index cases t hat fulfi lled t he Ghent crit eria, no FBN1 mut at ion was found.
Discussion
To t he best of our knowledge t his is t he first genot ypic descript ion of Port uguese pat ient s wit h MFS.
The percent age of pat ient s fulfi lling t he Ghent crit eria in whom mut at ions were det ect ed was slight ly lower t han in t he lit erat ure 10, 11 (79 % vs. 90 %, respect ively), but t his may be due t o t he wide confi dence int erval (64.4 %-93.6 %) result ing from t he small sample size.
The high frequency of new mut at ions (10 out of 12) support s current t hinking t hat most MFS pat ient s are carriers of a genet ic variant unique t o t heir family.
Int erest ingly, t he t ype and dist ribut ion of mut at ions in our pat ient s were signifi cant ly different from t hose in published dat a 9, 12 . We found 36 % missense mut at ions and 50 % leading t o a premat ure t erminat ion codon. As expect ed, most carriers of a PTC mut at ion did not present ect opia lent is 9 . In t he lit erat ure, missense mut at ions account for t wo-t hirds of FBN1 mut at ions, most of which affect cyst eine residues associat ed wit h cbEGF unit s and t hus int erfere wit h disulfi de bonds and prot ein st abilit y. Individuals wit h such mut at ions are more likely t o have ect opia lent is 12 . The rest usually have PTC mut at ions, leading t o t he format ion of incomplet e prot eins t hat int erfere wit h normal prot ein polymerizat ion (dominant negat ive effect ) 13 or result in funct ionally inact ive prot eins t hrough RNA degradat ion, reducing t he t ot al quant it y of fibrillin-1 (haploinsufficiency) 10, 14 . Individuals wit h t hese mut at ions t end t o present more severe musculoskelet al alt erat ions, part icularly j oint hypermobilit y, great er propensit y for aort ic dissect ion 9, 15 , and a significant ly lower risk for ocular involvement 9 , alt hough t here is no direct relat ionship bet ween phenot ype severit y and t he quant it y of mut ant t ranscript .
Our result s may have been infl uenced by select ion bias. As t he series is from a t ert iary care cent er, a large proport ion of t he pat ient s fulfi lled t he Ghent crit eria (bot h cardiovascular and musculoskelet al) and t herefore nonsense mut at ions would be likely t o be more prevalent 9, 12 .
The fact t hat we discovered t wo different mut at ions in one pat ient highlight s t he value of complet e sequencing of t he FBN1 gene, part icularly in cert ain pat ient s. The few cases in t he lit erat ure of compound het erozygosit y in MFS 16, 17 are charact erized by a more severe phenot ype. Mult iple mut at ions may also cont ribut e t o phenot ypic variabilit y wit hin families.
We did not ident ify any asympt omat ic carriers (t hose wit h FBN1 gene mut at ions but no maj or clinical manifest at ions). However, screening of relat ives revealed individuals wit h mild morphological abnormalit ies t hat were insuffi cient for a diagnosis of MFS but for whom we were t hen able t o provide appropriat e clinical monit oring and genet ic counseling. Excluding MFS in ot her relat ives, meanwhile, meant t hat t hey did not require periodic clinical assessment s or imaging st udies.
In t he t hree cases in which no mut at ion was found, it is possible t hat a mut at ion exist ed in t he promot er or non-coding int ronic regions of FBN1, or in large gene rearrangement s undet ect able by PCR; t here may also have been mut at ions in ot her genes, part icularly t hose coding for TGF-␤ t ype I and II recept ors (TGF-␤I and TGF-␤II) 18 .
Conclusions
In t his st udy we have highlight ed t he need for mult idisciplinary clinical evaluat ion of MFS pat ient s and t heir relat ives.
By describing 10 new mut at ions, we have broadened t he spect rum of known FBN1 mut at ions associat ed wit h MFS.
A bet t er underst anding of t he et iopat hology of Marfan syndrome, including molecular st udy, may lead t o t he discovery of new prognost ic markers and earlier ident ificat ion of candidat es for t herapeut ic int ervent ions 9 . 
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